Literature DB >> 26155327

Lichenoid Reactions in Association with Tumor Necrosis Factor Alpha Inhibitors: A Review of the Literature and Addition of a Fourth Lichenoid Reaction.

Morgan McCarty1, Amy Basile1, Brooke Bair1, David Fivenson1.   

Abstract

In this manuscript, a clinical case of a patient treated with adalimumab for Behcet's disease develops lichen planopilaris. A variety of mucocutaneous lichenoid eruptions have recently been described in association with tumor necrosis factor alpha inhibitors. The authors briefly discuss the clinical and pathological presentation of lichen planopilaris as well as a potential pathogenesis of cutaneous adverse effects seen as the result of tumor necrosis factor alpha inhibitor therapy. They review all case reports of lichen planopilaris occurring on tumor necrosis factor alpha inhibitors and suggest its classification as a fourth recognized pattern on this therapy.

Entities:  

Year:  2015        PMID: 26155327      PMCID: PMC4479369     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  25 in total

1.  Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern.

Authors:  Gloria Vergara; Juan Francisco Silvestre; Isabel Betlloch; Paloma Vela; María Pilar Albares; José Carlos Pascual
Journal:  Arch Dermatol       Date:  2002-09

2.  Successful treatment of lichen planus with adalimumab.

Authors:  Peter Holló; Josef Szakonyi; Dorottya Kiss; Hajnalka Jokai; Attila Horváth; Sarolta Kárpáti
Journal:  Acta Derm Venereol       Date:  2012-07       Impact factor: 4.437

3.  Onset of lichen planus during treatment with etanercept.

Authors:  Maria Letizia Musumeci; Francesco Lacarrubba; Giuseppe Micali
Journal:  Am J Clin Dermatol       Date:  2010       Impact factor: 7.403

4.  Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab.

Authors:  A C Moss; N S Treister; D K Marsee; A S Cheifetz
Journal:  Gastroenterology       Date:  2007-02       Impact factor: 22.682

5.  Lichen planus associated with etanercept.

Authors:  M Battistella; J Rivet; H Bachelez; F Lioté
Journal:  Br J Dermatol       Date:  2007-10-18       Impact factor: 9.302

6.  Lichenoid reaction induced by adalimumab.

Authors:  C De Simone; G Caldarola; M D'Agostino; M Rotoli; R Capizzi; P Amerio
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-11-14       Impact factor: 6.166

7.  Lichen planopilaris noted during etanercept therapy in a child with severe psoriasis.

Authors:  Naheed R Abbasi; Seth J Orlow
Journal:  Pediatr Dermatol       Date:  2009 Jan-Feb       Impact factor: 1.588

Review 8.  TNF receptor 2 pathway: drug target for autoimmune diseases.

Authors:  Denise Faustman; Miriam Davis
Journal:  Nat Rev Drug Discov       Date:  2010-05-21       Impact factor: 84.694

9.  Infliximab-induced lichen planopilaris.

Authors:  Rosa Fernández-Torres; Sabela Paradela; Luis Valbuena; Eduardo Fonseca
Journal:  Ann Pharmacother       Date:  2010-08-11       Impact factor: 3.154

10.  Skin reaction to adalimumab.

Authors:  W Beuthien; H-U Mellinghoff; J von Kempis
Journal:  Arthritis Rheum       Date:  2004-05
View more
  4 in total

1.  Expression and Significance of TNF-α and NF-κB/p65 in Cutaneous Lichen Planus.

Authors:  Jun Fang Chen; Xue Mei Zhang; Kiran Sanjel; Juan Zhang; Cong Ma
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-02

Review 2.  Arthropathy in Dermatology: A Comprehensive Review.

Authors:  Soumya Jagadeesan; Padmanabha Shenoy
Journal:  Indian Dermatol Online J       Date:  2017 Mar-Apr

3.  Lichen planopilaris induced by infliximab: A case report.

Authors:  Meghan L McPhie; Ami Wang; Sonja Molin; Thomas Herzinger
Journal:  SAGE Open Med Case Rep       Date:  2020-01-28

Review 4.  Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review.

Authors:  Jo L W Lambert; Sofie De Schepper; Reinhart Speeckaert
Journal:  J Clin Med       Date:  2021-03-03       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.